Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Torsten Haack"'
Autor:
Irina Velikyan, Martin Bossart, Torsten Haack, Iina Laitinen, Sergio Estrada, Lars Johansson, Stefan Pierrou, Michael Wagner, Olof Eriksson
Publikováno v:
Pharmaceuticals, Vol 16, Iss 1, p 61 (2022)
Imaging and radiotherapy targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR) could potentially benefit the management of neuroendocrine neoplasms (NENs), complementing clinically established radiopharmaceuticals. The aim of thi
Externí odkaz:
https://doaj.org/article/2a0daae7f48e4c97b40b55736a8c6764
Autor:
Irina Velikyan, Torsten Haack, Martin Bossart, Andreas Evers, Iina Laitinen, Philip Larsen, Oliver Plettenburg, Lars Johansson, Stefan Pierrou, Michael Wagner, Olof Eriksson
Publikováno v:
EJNMMI Research, Vol 9, Iss 1, Pp 1-13 (2019)
Abstract The glucagon receptor (GCGR) is emerging as an important target in anti-diabetic therapy, especially as part of the pharmacology of dual glucagon-like peptide-1/glucagon (GLP-1/GCG) receptor agonists. However, currently, there are no suitabl
Externí odkaz:
https://doaj.org/article/319da706f4c14a3d943426510f998c0c
Autor:
Michael Wagner, Johan G. Doverfjord, Joachim Tillner, Gunnar Antoni, Torsten Haack, Martin Bossart, Iina Laitinen, Lars Johansson, Stefan Pierrou, Olof Eriksson, Irina Velikyan
Publikováno v:
Pharmaceuticals, Vol 13, Iss 8, p 176 (2020)
Introduction: [68Ga]Ga-DO3A-VS-Cys40-Tuna-2 (previously published as [68Ga]Ga-DO3A-VS-Cys40-S01-GCG) has shown high-affinity specific binding to the glucagon receptor (GCGR) in vitro and in vivo in rats and non-human primates in our previous studies,
Externí odkaz:
https://doaj.org/article/05e00a5305104bf58ca9c45f37c8cb62
Autor:
Katrin Lorenz, Lars Johansson, Oliver Plettenburg, Iina Laitinen, Andreas Evers, Stefan Pierrou, Michael Wagner, Philip J. Larsen, Martin Bossart, Torsten Haack, Olof Eriksson, Irina Velikyan
Publikováno v:
Diabetes 70, 842-853 (2021)
Targeting of the Glucose-dependent Insulinotropic Polypeptide receptor GIPR is an emerging strategy in anti-diabetic drug development. The aim of this study was to develop a Positron Emission Tomography (PET) radioligand for the GIPR, to enable the a
Autor:
Jan Erik Berglund, Irina Velikyan, Torsten Haack, Iina Laitinen, Michael Wagner, Martin Bossart, Olof Eriksson, Gunnar Antoni, Philip J. Larsen, Lars Johansson, Stefan Pierrou, Joachim Tillner
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 63(5)
Introduction: The Glucagon Like Peptide-1 receptor (GLP1R) is a gut hormone receptor, intricately linked to regulation of blood glucose homeostasis via several mechanisms. It is an established and emergent drug target in metabolic disease. Positron E
Autor:
Gunnar Antoni, Martin Bossart, Torsten Haack, Irina Velikyan, J. Tillner, Johan G. Doverfjord, Olof Eriksson, Michael Wagner, Iina Laitinen, Lars Johansson, Stefan Pierrou
Publikováno v:
Pharmaceuticals
Volume 13
Issue 8
Pharmaceuticals, Vol 13, Iss 176, p 176 (2020)
Volume 13
Issue 8
Pharmaceuticals, Vol 13, Iss 176, p 176 (2020)
Introduction: [68Ga]Ga-DO3A-VS-Cys40-Tuna-2 (previously published as [68Ga]Ga-DO3A-VS-Cys40-S01-GCG) has shown high-affinity specific binding to the glucagon receptor (GCGR) in vitro and in vivo in rats and non-human primates in our previous studies,
Autor:
Olof, Eriksson, Irina, Velikyan, Torsten, Haack, Martin, Bossart, Iina, Laitinen, Philip J, Larsen, Jan Erik, Berglund, Gunnar, Antoni, Lars, Johansson, Stefan, Pierrou, Joachim, Tillner, Michael, Wagner
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 62(6)
Despite the importance of the glucagon receptor (GCGR) in disease and in pharmaceutical drug development, there is a lack of specific and sensitive biomarkers of its activation in humans. The PET radioligand
Autor:
Corinne Rocher, Aimo Kannt, Andreas Nygaard Madsen, Torsten Haack, Ralf Elvert, Tim Klöckener, Andreas Evers, Wolfgang Hennerici, Zsolt Bocskei, Bart Staels, Jean-Claude Guillemot, Katrin Lorenz, Michael Wagner, Vincent Mikol, Martin Bossart, François Pattou, Claire Kammermeier
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ec5853457dab57752d19eead36f87dd
https://doi.org/10.1111/dom.14035/v2/response1
https://doi.org/10.1111/dom.14035/v2/response1
Autor:
Torsten Haack, Anja Schüler, Michael Wagner, Stefania Pfeiffer-Marek, Robert Seckler, Anja Thalhammer, Michael Kurz, Martin Wolff, Norbert Nagel, Klaus Gast, Andreas Evers
Dual glucagon-like peptide-1/glucagon receptor agonists have emerged as promising candidates for the treatment of diabetes and obesity. Issues of degradation sensitivity and rapid renal clearance are addressed, for example, by the conjugation of pept
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b509c9c2688b5820336fba7b7e4ec86f
https://publishup.uni-potsdam.de/frontdoor/index/index/docId/58821
https://publishup.uni-potsdam.de/frontdoor/index/index/docId/58821
Autor:
Irina Velikyan, Veronique Tavernier, Olof Eriksson, Lars Johansson, Stefan Pierrou, Gunnar Antoni, Iina Laitinen, Michael Wagner, J. Tillner, Youssef Hijazi, Jan Erik Berglund, Lenore Teichert, Torsten Haack
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-10 (2020)
Scientific Reports
Scientific Reports
Unimolecular dual agonists for the glucagon-like peptide 1 receptor (GLP1R) and glucagon receptor (GCGR) are emerging as a potential new class of important therapeutics in type 2 diabetes (T2D). Reliable and quantitative assessments of in vivo occupa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a538fad419d890a7cbfab3a436036ef
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-424041
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-424041